Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | GRM5 | P41594 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4263851 | 0.84 | GRM5 (0.64) | LMNACYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL3675956 | 0.82 | LMNA (0.52) | LMNACYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL4256779 | 0.81 | TRPV1 (0.39) | LMNACYP1A2CYP2C9CYP2C19TRPV1 | |
| SCHEMBL1253664 | 0.80 | TRPV1 (0.67) | TRPV1 | |
| SCHEMBL2841920 | 0.80 | TRPV1 (0.61) | TRPV1 | |
| SCHEMBL8298026 | 0.79 | TRPV1 (0.73) | TRPV1 | |
| SCHEMBL8299450 | 0.79 | TRPV1 (0.75) | TRPV1 | |
| SCHEMBL781659 | 0.77 | CYP1A2 (0.87) | LMNACYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL1250889 | 0.77 | TRPV1 (0.68) | TRPV1HSD11B1 | |
| SCHEMBL135679 | 0.76 | LMNA (1.00) | LMNACYP1A2CYP2C9CYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680118-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680118-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8518916-B2 | Heterocyclic derivatives as M-GLU5 antagonists | RECORDATI IRELAND LIMITED (IE) | 2013-08-27 | — | — | US | disclosed |
| US-20130012541-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012541-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. (US) | 2013-01-10 | — | — | US | disclosed |
| US-8227467-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227467-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20110152324-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152324-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2011-06-23 | — | — | US | disclosed |
| CN-101821256-A | Novel heterocyclic compounds as mGlu5 antagonists | RECORDATI IRELAND LTD | 2010-09-01 | — | — | CN | disclosed |
| US-7683063-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683063-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2010-03-23 | — | — | US | disclosed |
| EP-2060260-A1 | Therapeutic agents useful for treating pain | Euro-Celtique S.A. (LU) | 2009-05-20 | — | — | EP | disclosed |
| US-20090042841-A1 | NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2009-02-12 | — | — | US | disclosed |
| EP-1862458-A2 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2007-12-05 | — | — | EP | disclosed |
| EP-1631285-B1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | EURO CELTIQUE SA (LU) | 2007-08-08 | — | — | EP | disclosed |
| US-20070027159-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2007-02-01 | — | — | US | disclosed |
| US-20070027159-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2007-02-01 | — | — | US | disclosed |
| WO-2005004866-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | EURO-CELTIQUE, S.A. (LU) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027159-A1 | Therapeutic agents useful for treating pain | ARRB1, FPR1, OPRL1 | LMNA 4683/4885CYP1A2 1476/4885CYP2C9 2902/4885 |
| US-20130012541-A1 | Therapeutic Agents Useful for Treating Pain | ARRB1, FPR1, OPRL1 | LMNA 4683/4885CYP1A2 1476/4885CYP2C9 2902/4885 |
| US-20110152324-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | ARRB1, FPR1, OPRL1 | LMNA 4683/4885CYP1A2 1476/4885CYP2C9 2902/4885 |
| US-20090042841-A1 | NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | GRM5, GRIK5, GRM3 | LMNA 3472/4885CYP1A2 3224/4885CYP2C9 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.